Clinical Trials Browser

INDUSTRY × Central Nervous System Diseases × Temozolomide × Clear all

NCT07326566 2026-06-05

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Phase 2 Recruiting

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma